Blog

Jan 29, 2025, 18:07

The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 – European Society for Medical Oncology

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 significantly improves the pathological complete response rate in patients with high-risk, early-stage ER+/HER2− Breast Cancer.

Read the full news on ESMO Daily Reporter.”

pembrolizumab

Breast Cancer cancer ESMO ESMO Daily Reporter European Society for Medical Oncology fight against cancer Global fight against cancer HER2 KEYNOTE-756 neoadjuvant chemotherapy OncoDaily Oncology pembrolizumab

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more